Benjamin George, MD
Medical Oncology · Colby, KSNPI 1811968225
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $325,724 of the $432,539 with a category attached, or 75.3%. E.r. Squibb & Sons, L.L.C. accounts for 87.9% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $117,091 and has fallen 64.1% since, to $42,085 in 2025. Among medical oncology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $1456.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$380K
- AstraZeneca$14K
- TG Therapeutics, Inc.$13K
- Janssen Scientific Affairs, LLC$9K
- Bristol Myers Squibb$6K
- GSK$3K
- plus $7K from 31 others
Across 69 payments — averaging $9580.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Karyopharm Therapeutics Inc.$460K
- Seagen Inc.$148K
- Epizyme, Inc.$31K
- Napo Pharmaceuticals Inc$23K
- Eli Lilly$246
What the payments were for
- Consulting fees$60,97614%
- Speaking & faculty fees$325,72475%
- Travel & lodging$40,1519%
- Food & beverage$5,5371%
- Education$1510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 202 | $380,015 |
| AstraZeneca | 12 | $14,376 |
| TG Therapeutics, Inc. | 10 | $12,944 |
| Janssen Scientific Affairs, LLC | 8 | $9,435 |
| Bristol Myers Squibb(2 entities) | 6 | $5,566 |
| GSK | 1 | $2,750 |
| Karyopharm Therapeutics Inc. | 1 | $2,250 |
| Seagen Inc. | 2 | $1,475 |
| Taiho Oncology, Inc. | 1 | $1,250 |
| Johnson & Johnson | 7 | $1,090 |
| Amgen | 3 | $143 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $139 |
| Genmab U.S., Inc. | 1 | $123 |
| Pfizer | 7 | $116 |
| Menarini Silicon Biosystems, Inc. | 1 | $113 |
| Regeneron Healthcare Solutions, Inc. | 3 | $112 |
| Adaptive Biotechnologies Corporation | 1 | $97 |
| Gilead(2 entities) | 2 | $64 |
| Myriad Genetic Laboratories, Inc. | 2 | $51 |
| Array Biopharma Inc | 2 | $38 |
| Genentech USA, Inc. | 2 | $37 |
| AbbVie | 2 | $37 |
| Servier Pharmaceuticals LLC | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| CTI Biopharma Corp. | 2 | $27 |
| Lilly USA, LLC | 1 | $26 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $25 |
| Myovant Sciences Inc. | 1 | $24 |
| Merck | 2 | $24 |
| Geron Corporation | 1 | $20 |
| Bayer | 1 | $17 |
| Tesaro, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Exelixis Inc. | 1 | $15 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| EMD Serono, Inc. | 1 | $13 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$432,539 in reported general payments places this provider in the 95th percentile of 25 medical oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 29 | $365,089 |
| RevlimidLenalidomide | 17 | $263,528 |
| ImbruvicaIbrutinib | 16 | $263,192 |
| VerzenioAbemaciclib | 11 | $162,176 |
| Abiraterone Acetate | 21 | $29,287 |
| Everolimus | 12 | $26,192 |
| EliquisApixaban | 12 | $6,860 |
| Enoxaparin Sodium | 12 | $3,494 |
| Anastrozole | 63 | $1,365 |
| Dexamethasone | 69 | $924 |
| Prochlorperazine Maleate | 54 | $667 |
| Acyclovir | 49 | $621 |
| Letrozole | 39 | $554 |
| Ondansetron Hcl | 43 | $506 |
| Tamoxifen Citrate | 24 | $431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $5,566 | $263,52817 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $139 | $263,19216 claims |
| Lilly USA, LLCVerzenio | $26 | $162,17611 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $9,435 | $29,28721 claims |
| PfizerEliquis | $116 | $6,86012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 medical oncology providers in Kansas.
Other medical oncology in Colby
- Anne OdeaWestwood$2.1M
- Weijing SunWestwood$150K
- Anwaar SaeedWestwood$126K
- Elizabeth WulffWestwood$65K
- Joseph MooreWichita$41K
- Anis ToumehGarden City$40K
- Ajjai AlvaOverland Park$25K
- Joaquina BarandaWestwood$18K
- Elshami ElaminNewton$17K
- Mark FesenGreat Bend$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.